Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.
Also called NCT03386539
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 211 participants
- Registry
-
NCT03386539
-
- Main results
- Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03386539. Randomized; single masking; primary purpose treatment. Start 2018-01-29 (actual); primary completion 2023-04-17 (actual). Results posted on 2026-07-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
- Acronym
- TEAMMATE
- Condition
- Pediatric Heart Transplantation
- Condition
- Immunosuppression
- Condition
- Chronic Kidney Diseases
- Condition
- Cardiac Allograft Vasculopathy
- Condition
- Heart Transplant Failure and Rejection
- Condition
- Post-transplant Lymphoproliferative Disorder
- Condition
- Heart Transplant Infection
- Intervention (Drug)
- Everolimus
- Intervention (Drug)
- Tacrolimus
- Intervention (Drug)
- Mycophenolate Mofetil
- Lead sponsor
- Boston Children's Hospital
- Collaborator
- Stanford University
- Collaborator
- United States Department of Defense
Record details
- Record id
cardio:ct-nct03386539- Content hash
38efecc9b57fa942cd90d44e1ea4054c4eea55f819f5ad654d69730d484f3114